AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
SHARE - Symbicort and Health Economics in a Real Life Evaluation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1970
- Registration Number
- NCT00259766
- Locations
- 🇸🇪
Reseearch Site, Perstorp, Sweden
🇸🇪Research Site, Örebro, Sweden
🇸🇪Research site, Ödeshög, Sweden
SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00259792
- Locations
- 🇫🇷
Research Sites, Creteil, France
🇫🇷Research Site, Marcq En Baroeul, France
🇫🇷Research site, Luneville, France
Comparison Between Symbicort® and Prednisolone in COPD
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00259779
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00259090
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 270
- Registration Number
- NCT00259077
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00259051
- Locations
- 🇯🇵
Research Site, Yamato, Japan
Iressa v BSC (Best Supportive Care) in First Line NSCLC
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 216
- Registration Number
- NCT00259064
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Phase II Iressa Versus Vinorelbine (INVITE)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT00256711
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 655
- Registration Number
- NCT00257205
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00256698
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
© Copyright 2024. All Rights Reserved by MedPath